Abstract
<i>Helicobacter pylori</i> infection has been associated with various gastric diseases, including ulcers, adenomas, and adenocarcinomas. Over 40 years since the discovery of <i>H. pylori</i>, numerous studies have shown that <i>H. pylori</i> eradication therapy can help prevent gastric cancer not only in healthy individuals but also in patients who have already been treated for early gastric cancer. Moreover, some studies have shown that eradication therapy can improve gastric mucosal inflammatory diseases, such as atrophic changes and intestinal metaplasia. This article reviews the epidemiology of <i>H. pylori</i> infections and gastric cancer, mechanisms of <i>H. pylori</i>-associated gastric cancer development, and current evidence supporting the benefits of <i>H. pylori</i> eradication for reducing or preventing gastric cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
